described after infection with live pathogens, but studies involving immunization with protein antigen have indicated a strong reliance on IL-4 for Th2 activation. Additional factors, such as initial route of exposure to foreign antigen or pathogen may also account for differences in the IL-4 dependence of Th2 responses in these models. More information is needed to clarify the extent to which IL-4 plays a role in the type of Th2 responses generated by atopic individuals in response to environmental allergen exposure.
To determine the contribution of IL-4 to the preferential Th2 activation demonstrated by atopic individuals, we investigated the role of IL-4 in Th2 responses generated at anatomic sites where environmental allergens are normally encountered, namely the airway and skin. We have established sensitization protocols that result in strong Th2 activation involving initial exposure of mice to soluble ovalbumin (OVA), either by inhalation or epicutaneous (e.c.) application under an occlusive skin patch. Using IL-4 -/-mice, we show that Th2 responses to inhaled (i.n.) OVA are diminished in the absence of IL-4, whereas Th2 responses after e.c. exposure to OVA remain intact. However, epicutaneously induced Th2 responses were not seen when Stat6 -/-mice (which are deficient in signal transducer and activator of transcription 6) were exposed to OVA. Instead, these mice mounted Th1-type responses. Thus, e.c. OVA exposure could induce Th2 activation independently of IL-4, but not independently of STAT6, suggesting that IL-13, another known activator of the STAT6 signaling pathway, might be involved. In vivo IL-13 depletion of epicutaneously sensitized IL-4 -/-mice led to a loss of Th2 responses, confirming this hypothesis. These data implicate the skin of atopic persons as a potentially important site of initial Th2 sensitization to environmental allergens, perhaps allowing sensitization to occur even more readily than through the airway.
Methods
Animals. C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). IL-4 -/-mice (C57BL/6J-Il4 tm2Nnt ) were obtained from The Jackson Laboratory and then subsequently bred in our facilities. Stat6 -/-mice on a B6/129 background were provided by Dr. James Ihle (St. Jude's Research Center, Memphis, Tennessee, USA), and were bred and maintained in our facilities. Female mice, 8-12 weeks of age, were used in all experiments.
Sensitization protocols. For e.c. sensitization, mice had their backs shaved with electric clippers. One to 2 days later (day 0), 100 µL of either OVA (Grade V; Sigma Chemical Co., St. Louis, Missouri, USA) (1.0 mg/mL) in PBS or PBS alone was applied to gauze in the center of an occlusive patch (DuoDERM Extra Thin; ConvaTec, Princeton, New Jersey, USA), which was then affixed to their backs. Patches were left intact for 4 days, with application of a second patch on day 14 in some cases. For i.n. sensitization, mice were anesthetized lightly with methoxyflurane (Metofane; Mallinckrodt Veterinary Inc. Mundelein, Illinois, USA) and then administered 50 µL of either OVA (2 mg/mL) in PBS or PBS alone by intranasal droplet application on days 0, 1, and 2.
Airway challenge. Beginning on day 14 after e.c. or i.n. sensitization, mice were challenged with i.n. OVA over a 6-day period. Mice were anesthetized with methoxyflurane and then administered 50 µL of OVA in PBS (0.5 mg/mL) by intranasal droplet on days 14, 15, 18, and 19. Mice were sacrificed on day 21 for assessment of lung inflammatory responses.
In vivo IL-13 depletion. To block IL-13 activity in vivo, a soluble IL-13 receptor α2-Fc fusion protein (IL-13Rα-Fc), kindly provided by Genetics Institute Inc. (Cambridge, Massachusetts, USA) was used. IL-13Rα-Fc and control human IgG (ctrl-Fc) were prepared as described previously (30) . IL-4 -/-mice were injected intraperitoneally with 200 µg of either IL-13Rα-Fc or ctrl-Fc in 500 µL of PBS every other day, from day -1 to day 19 of the e.c. sensitization and airway challenge protocols described above.
Analysis of bronchoalveolar lavage (BAL) fluid. After mice were sacrificed by CO 2 asphyxiation, BAL was performed by cannulation of the trachea, followed by lavage of airway lumina 3 times with 1 mL of PBS. After cells were washed and counted, cytospin preparations were stained with Diff-Quik (Dade Behring Inc., Newark, Delaware, USA). Differential cell counts were based on morphology and staining characteristics of 200 cells per sample.
Lung histology. Lungs were prepared by perfusion via the right ventricle with 20 mL of PBS and inflation with 1.0 mL of formalin. Paraffin-embedded lungs were sectioned in the coronal plane, ensuring that central airways were visible. Sections (5 µm thick) were stained with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS). A histologic inflammation index was determined by scoring H&E-stained sections for amount and density of perivascular, peribronchiolar, and when present, interstitial infiltrate in a blinded fashion on a subjective 12-point scale (1 = minimal to absent infiltrate; 12 = florid infiltrate, diffusely involving the peribronchiolar regions and pulmonary interstitium). Lungs from individual mice were scored twice by a single investigator, and the average score was used as the index value for that animal. Data are reported as mean ± SEM of the index value.
Isolation of lung inflammatory cells. In some experiments, cells were isolated from lung tissue on day 21 by enzymatic digestion. Lungs from several mice were pooled, manually minced into fragments (1-2 mm), and incubated at 37°C for 20 minutes in a digestion mixture consisting of Click's medium (GIBCO BRL, Grand Island, New York, USA), 10% FCS, 150 U/mL collagenase (Worthington Biochemical Corporation, Freehold, New Jersey, USA), and 20 µg/mL DNase I Type IV from bovine pancreas (Sigma Chemical Co.). After digestion, tissue was pushed through a metal strainer, filtered through nylon mesh, and centrifuged over a Ficoll gradient (LSM; ICN Biomedicals Inc., Aurora, Ohio, USA) to isolate mononuclear cells.
Cytokine production by lung cells. Syngeneic T cell-depleted splenocytes were used as antigen-presenting cells and were prepared by antibody-mediated complement lysis, using antibodies to CD4 (GK1.5), CD8 (TIB 105), and Thy1 (Y19), followed by treatment with mitomycin C. Lung cells (2 × 10 6 /mL) were cultured with antigen-presenting cells (2 × 10 6 /mL) and OVA (100 µg/mL) in Click's medium with 5% FCS at 37°C for 48 hours. Cytokines in culture supernatants were detected using commercially available ELISA kits (IFN-γ, IL-4, IL-5, or IL-13). The IL-13 ELISA kit was purchased from R&D Systems (Minneapolis, Minnesota, USA); all others were from Endogen Inc. (Woburn, Massachusetts, USA). The lower limit of sensitivity for each ELISA was 0.6 ng/mL (IFN-γ), 18 pg/mL (IL-4), 63 pg/mL (IL-5), and 6 pg/mL (IL-13).
Flow cytometry. Cells were preincubated with rat antimouse Fc receptor antibody (24G2) before staining with Quantum Red-conjugated anti-CD4 (clone H129.19; Sigma Chemical Co.) and PE-conjugated anti-CD8 (Ly-3.2; 53-5.8; PharMingen, San Diego, California, USA).
Antibody measurement by ELISA. For most experiments, serum was collected on day 13 after e.c. or i.n. sensitization, and again at the time of sacrifice on day 21. For studies in which mice received 2 e.c. OVA exposures, serum was obtained on days 13 and 27.
For determination of OVA-specific antibodies, 96-well microtiter plates (Nalge Nunc International, Rochester, New York, USA) were coated with OVA (50 µg/mL; Sigma Chemical Co.) in 0.1 M NaHCO 3 at 4°C overnight. The following steps were performed, with plates being washed 3 times with PBS/0.05% Tween-20 between each step. Blocking was performed with 1% BSA in borate saline (BSA-BS) for 1 hour at 37°C, and then sera were diluted serially in 1% BSA-BS/0.05% Tween-20 for 1 hour at 37°C. This was followed by (incubation for 1 hour at 37°C with an optimal dilution) of one of the following biotinlabeled secondary rat anti-mouse antibodies: either anti-IgG1 (LO-MG1-15 from BioSource International, Camarillo, California, USA), anti-IgG2a (R19-15; PharMingen), or anti-IgE (2379-04S; BioSource International). Streptavidin-conjugated horseradish peroxidase was added for a 30-minute incubation at 37°C, followed by addition of TMB substrate solution (DAKO Corp., Carpinteria, California, USA), and then termination of the reaction with 6 N HCl. Color change was read at 405 nm on a microplate ELISA reader (Bio-Tek Instruments Inc., Winooski, Vermont, USA). Antibody concentrations were calculated by comparison to standards: monoclonal anti-OVA mouse IgG1 (clone OVA-14; Sigma Chemical Co.); monoclonal anti-OVA mouse IgE (kindly provided by E. Gelfand, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado, USA); and pooled hyperimmune serum with high-titer anti-OVA IgG2a (concentration arbitrarily set at 200 U/mL) generated by repeated intraperitoneal injection of IL-4 -/-mice with OVA in alum.
Total serum IgE levels were measured in a similar ELISA with changes as follows. The coating was done with anti-mouse IgE (The Binding Site, Birmingham, United Kingdom) in borate saline at 4°C overnight; the standard was mouse IgE (IgE-3; PharMingen); and the biotin-labeled secondary antibody was rat anti-mouse IgE (LO-ME-3; BioSource International).
Statistical analyses. Statistical significance was determined using an unpaired Student's t test. Figure 1a) . Furthermore, systemic Th2 activation was also evidenced in these mice by the type of inflammatory response generated in the airway upon challenge with i.n. OVA. As shown in Figure 1b , mice that had been epicutaneously sensitized and then challenged with i.n. OVA over a 6-day period showed significant increases in both the total number of cells (P = 0.005) and the number of eosinophils (P = 0.0004) recovered by BAL, compared with unsensitized mice similarly exposed to i.n. OVA. In addition, PAS staining of lung sections demonstrated strong induction of PAS-positive mucus secretion in airways (see Figure 4a below). Other researchers have shown that overexpression of either IL-4 or IL-5 in the lung leads to increased mucus production (33, 34) . Furthermore, studies from our laboratory using adoptive transfer of in vitro-generated Th1 or Th2 cells have established that recruitment of Th2 cells specifically to the airway is associated with eosinophilia and mucus hypersecretion, whereas Th1 cells are associated with neutrophils and little to no mucus production (35) . Thus, both the high number of eosinophils and induction of mucus secretion in lungs after airway challenge of epicutaneously sensitized mice support the presence of Th2 effector cells. To confirm this, inflammatory cells were recovered from lung tissue by enzymatic digestion, and then restimulated in vitro with OVA. As shown in Figure 1c , the Th2 cytokines IL-4, IL-5, and IL-13 were all detected in culture supernatants, whereas IFN-γ, a Th1-associated cytokine, was not. Taken together, these data demonstrate highly skewed Th2 activation in our system after e.c. exposure to soluble OVA.
Results

Th2
We also studied immune responses initially generated through the airway, for comparison with the epicutaneously induced Th2 responses described above. Primary exposure of mice to soluble i.n. OVA on 3 consecutive days also induced immune responses with characteristics of Th2 activation, as demonstrated by (a) high levels of OVA-specific IgG1 in serum ( Figure 2a) ; (b) airway infiltrates with significantly higher numbers of eosinophils than were found in PBS-exposed controls after secondary airway challenge with OVA ( Figure 2b below). In addition, although OVA-specific IgE was detectable in only a minority of the inhalation-sensitized mice, total IgE was elevated in all of them ( Figure  2a ). It should be noted that Th2 skewing after inhalation priming was preferential -rather than absolute as seen in epicutaneously sensitized mice -in that IFN-γ was also detected in cultures of lung inflammatory cells (Figure 2c ), and some mice demonstrated OVA-specific IgG2a responses, an isotype associated with IFN-γ production by Th1 cells (Figure 2a ). However, neither the preferential Th2 induction by i.n. sensitization nor the Th2 responses generated after e.c. OVA exposure could be attributed to an antigen dose effect. Dose-response studies performed using a wide range of OVA (0.1-1,000 µg) for both i.n. and e.c. sensitization showed no change in the type of response induced with different OVA doses. Serum antibody levels and total BAL fluid numbers did rise with increasing OVA dose, but the antibody isotype pattern and high percentage of eosinophils in BAL fluid remained the same (not shown). Optimal responses in this study were reached with the 100-µg sensitizing dose. In summary, the ability to generate strong Th2 activation in the absence of an adjuvant such as alum, at both these anatomic sites that would normally encounter environmental allergens, supports the particular relevance of using these models for investigation of the critical immunoregulatory factors involved in atopic responses.
IL-4-deficient mice show impaired Th2 responses after primary i.n. OVA exposure. Our goal was to investigate the importance of IL-4 in generation of Th2 responses at sites where environmental allergens are normally encountered, namely the skin and airway. IL-4 -/-mice were initially exposed to either e.c. or i.n. OVA as above, and then challenged with OVA via the airway. As shown in Figure 3 , although airway inflammatory responses were still induced in IL-4 -/-mice initially exposed to i.n. OVA, these responses had characteristics of predominant Th1 activation, with little evidence of the Th2 responses seen in wild-type (WT) mice. Specifically, the number of eosinophils in BAL fluid was significantly reduced in IL-4 -/-mice compared with WT mice (P = 0.0007), whereas the number of neutrophils was modestly increased (Figure 3a) . Furthermore, mucus secretion, another indicator of Th2 activation, was diminished in lungs of inhalation-primed IL-4 -/-mice, as indicated by decreased PAS staining of airways compared with WT controls (Figure 4 , g and e, respectively). This was despite equivalent amounts of inflammation being present in the lungs of IL-4 -/-mice and WT mice, as judged by scoring of histologic sections (not shown; see Methods for description of histologic inflammation index). Histologic examination also revealed a marked reduction in eosinophils in lungs of inhalation-sensitized IL-4 -/-mice compared with WT mice, which further supports a shift toward Th1 activation. Likewise, the antibody isotype profile in serum of IL-4 -/-mice was
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Figure 1
Th2 responses after e.c. OVA exposure. (a) Mice were exposed to e.c. OVA (100 µg) under an occlusive skin patch either once (on day 0) or twice (on days 0 and 14 (Figure 5a ). Mucus hypersecretion, as indicated by strongly positive PAS staining of airways, was also present (Figure 4c ). Of note, persistence of an eosinophilic response in lungs of epicutaneously sensitized, as opposed to inhalation-sensitized, IL-4 -/-mice was not a reflection of differences in the baseline eosinophil numbers present in lung or BAL fluid before airway challenge. Mice that had been either epicutaneously or inhalation sensitized, but not challenged with OVA, had similar total numbers of cells in BAL fluid on day 14: (1.2 ± 0.3) × 10 5 and (1.0 ± 0.1) × 10 5 , respectively. Furthermore, there was no increase in eosinophils in BAL fluid of mice sensitized by e.c. or i.n. OVA on day 14 compared with PBS-exposed mice (fewer than 0.01 × 10 5 eosinophils in all groups), nor was there any detectable increase in eosinophils in lung tissue by histologic analysis (not shown).
Analysis of OVA-specific antibodies in serum of epicutaneously sensitized IL-4 -/-mice did show a somewhat altered isotype profile, with reduced levels of OVA-specific IgG1 and IgE, and higher levels of anti-OVA IgG2a (Figure 5b ). The reduction in IgE observed in IL-4 -/-mice is not surprising, given that IL-4 is the major stimulus for isotype class switching to IgE. Thus, even if Th2 cells secreting IL-5 and IL-13 are present, they will not be able to stimulate high IgE levels without IL-4. Although the presence of OVA-specific IgG2a was variable in epicutaneously sensitized IL-4 -/-mice, we have never detected anti-OVA IgG2a in epicutaneously sensitized WT mice (n > 30). This raises the possibility that in the absence of IL-4, some Th1 activation may be occurring after e.c. OVA exposure. However, the cellular composition of BAL fluid from these mice does not support this, because equivalent numbers of neutrophils and eosinophils were present in WT and IL-4 -/-mice ( Figure  5a ). Thus, if Th1 activation had occurred, Th1 effector cells either were not recruited to the lung after i.n. OVA challenge, or were not at a level that would affect the Th2 response. Alternatively, higher IgG2a levels present in IL-4 -/-mice may simply reflect the specific lack of IL-4, which by decreasing class switching to IgG1 and IgE, may shift the balance to IgG2a.
To clarify the issue of whether Th1 effector cells, along with Th2 cells, were present in the lungs of epicutaneously sensitized IL-4 -/-mice after airway challenge, further analysis of lung tissue infiltrates was undertaken. The overall amount of inflammation present in lung sections was first assessed using a histologic index based on the number of airways and vascular profiles surrounded by inflammatory cells, and the density of these infiltrates. As shown in Figure 6a , no detectable difference was seen between WT and IL-4 -/-mice in the amount of inflammation present in lungs after e.c. sensitization and airway challenge with OVA. Lung inflammatory cells were then isolated to determine relative numbers of T-cell subsets and cytokine secretion profiles. After initial e.c. OVA sensitization and subsequent i.n. OVA challenge of either WT or IL-4 -/-mice, lungs from several mice were pooled and inflammatory cells were isolated by enzymatic digestion. As shown in Figure 6b , equivalent numbers of cells were isolated from lungs of WT and IL-4 -/-mice, with similar numbers of CD4 and CD8 T cells present in the infiltrates of both groups. These cells were then restimulated in vitro by culture with OVA to determine their cytokine production profiles. Cells isolated from lungs of either WT mice or IL-4 -/-mice that had been epicutaneously sensitized with OVA before airway challenge secreted high levels of the Th2 cytokines IL-5 and IL-13 that were statistically indistinguishable, although the levels of both cytokines were somewhat lower in IL-4 -/-cultures than in WT cultures (Figure 6c ). These data confirm that Th2 activation did occur in epicutaneously sensitized IL-4 -/-mice. In contrast, no IFN-γ was detected in supernatants of IL-4 -/-lung inflammatory cell cultures. Thus, although the presence of OVA-specific IgG2a suggests that Th1 activation may have occurred in these mice, Th1 cells were either not recruited to the lung as effectively as were Th2 cells, or were not present in high enough numbers to be detectable.
STAT6 signaling is required for generation of Th2 responses after e.c. OVA exposure. The ability of IL-4 to induce differentiation of naive CD4 T cells into Th2 effector cells is critically linked to its ability to activate the STAT6 intracellular signaling pathway (36) (37) (38) . In other words, STAT6 activation itself, whether caused by IL-4 or another cytokine, is more precisely the true inducer of Th2 generation. We predicted, therefore, that the IL-4-independent Th2 responses induced by e.c. OVA exposure in our model would retain their dependence on STAT6 signaling. To test this hypothesis, mice deficient in STAT6 (Stat6 -/-) were exposed to e.c. OVA and subsequently challenged with i.n. OVA as described previously. Epicutaneously sensitized Stat6 -/-mice did mount airway inflammatory responses after i.n. OVA challenge, with significant increases in total BAL fluid cell numbers compared with PBS-exposed controls [(6.4 ± 1.1) × 10 5 vs. (1.2 ± 0.2) × 10 5 , respectively; P = 0.002; not shown]. However, as shown in Figure 7 , these responses had characteristics of Th1, rather than Th2, activation, with significantly reduced numbers of eosinophils (P < 0.0001) and increased numbers of neutrophils (P = 0.01) in BAL fluid compared with WT controls. Loss of Th2 activation was further supported by absence of PAS-positive staining of airways of inflamed lungs from Stat6 -/-mice (not shown). Not surprisingly, the antibody isotype profile in serum of epicutaneously sensitized Stat6 -/-mice also indicated Th1 activation by the marked decrease in OVA-specific IgG1 (12 ± 4.6 µg/mL; n = 7) compared with WT controls (137.9 ± 44.6 µg/mL; n = 5). In contrast, IgG2a levels were increased (34.8 ± 9 U/mL vs. undetectable, respectively). Thus, in contrast to a lack of requirement for IL-4, epicutaneously induced Th2 responses were dependent on STAT6 signaling. These data suggest that Th2 responses generated by e.c. sensitization of IL-4 -/-mice in this study resulted from activation of STAT6 by a factor other than IL-4.
Th2 responses are no longer generated after primary e.c. OVA exposure of IL-4 -/-mice depleted of IL-13. As stated above, the STAT6 dependence of Th2 responses generated by e.c. OVA exposure in our system suggested that epicutaneously induced Th2 responses present in IL-4 -/-mice must involve activation of STAT6 by some factor other than IL-4. We hypothesized that this factor was likely to be IL-13, a Th2-associated cytokine that shares many biologic functions with IL-4, including the ability to activate STAT6 (39, 40) . To investi-
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The gate the role of IL-13 in our system, IL-4 -/-mice were depleted of IL-13 in vivo by repeated administration of an IL-13 antagonist (IL-13Rα-Fc). IL-4 -/-mice, depleted or not of IL-13, were epicutaneously sensitized and then challenged with OVA through the airway. As shown in Figure 8 , mice treated with IL-13Rα-Fc had significantly fewer eosinophils in BAL fluid than did mice receiving the control Fc (P = 0.009), whereas the numbers of neutrophils were slightly increased. These results are consistent with a loss of the Th2 response, and a switch toward Th1 activation, as had been seen in Stat6 -/-mice. PAS-positive staining of airways was also absent in mice treated with the IL-13Rα-Fc antagonist (not shown). These data show that IL-13 is critical for the maintenance of Th2 activation in IL-4 -/-mice after primary e.c. OVA exposure.
Discussion
A critical requirement for developing new treatment strategies for atopic disease is better understanding of which immunoregulatory factors are responsible for the hallmark predisposition toward Th2 activation. The goal of this study was to assess the importance of IL-4, a known Th2-promoting cytokine, in generation of an allergic-type Th2 response through use of mouse models that closely mimic natural allergen exposure. Using IL-4 -/-mice, we investigated the role of IL-4 in Th2 responses induced by initial exposure of either the skin or airway to soluble protein, and identified a marked difference in the IL-4 requirement at these two sites. Th2 responses generated by initial airway exposure to OVA were highly dependent on IL-4, whereas epicutaneously induced Th2 responses were not. Instead, IL-13 was sufficient to generate Th2 responses after e.c. OVA exposure. The data provide particularly relevant insight into the potential for distinct Th2 activation requirements at two sites of environmental allergen encounter -the skin and lung -and suggest that the cutaneous microenvironment may more readily promote Th2 sensitization than was previously appreciated.
In our models, initial exposure of WT mice to soluble OVA either by inhalation or skin contact, in the absence of adjuvant, induced strong Th2 responses. This was demonstrated by a characteristic Th2-type antibody isotype profile in serum, with high levels of IgE and IgG1(both induced by IL-4), and little IgG2a, the murine isotype associated with IFN-γ production by Th1 cells (41, 42) . In addition, subsequent airway challenge of either epicutaneously or inhalation-sensitized mice led to lung responses with characteristics of Th2 recruitment (35) , including inflammatory infiltrates with high numbers of eosinophils, mucus hypersecretion, and production of Th2 cytokines (IL-4, IL-5, and IL-13) by lung inflammatory cells. The generation of robust Th2 responses after exposure of the skin to soluble OVA in our study is in agreement with other studies (31, 32) . We also report generation of Th2 responses after primary exposure of mice to OVA by inhalation, a finding that has not been widely reported in the literature. In fact, several studies examining the effects of primary aerosol exposure to protein have reported suppression or tolerance induction via this PAS staining of lung sections (×200) from epicutaneously or inhalation-sensitized mice after airway challenge with OVA. Mice were initially exposed to either e.c. or i.n. OVA or PBS. Beginning on day 14, all mice were challenged with i.n. OVA over a 6-day period, and lungs were harvested for histologic analysis on day 21.
route (43, 44) . One group, however, has reported effective sensitization of mice after exposure to aerosolized protein (45) . Subtle differences in the dose of antigen used or kinetics of delivery may explain the discrepancies in the literature. With regard to this study, the dose and time course of i.n. OVA exposure used consistently resulted in Th2 generation. Establishment of vigorous Th2 responses by primary exposure of mice to soluble OVA either through the skin or airway provides two particularly relevant models of allergen-induced Th2 activation, and studies aimed at addressing the role of IL-4 in these responses revealed interesting differences between these two sites of sensitization. After initial i.n. OVA exposure, IL-4 -/-mice showed diminished Th2 responses compared with WT controls, with subsequent airway challenge leading to infiltrates containing markedly decreased numbers of eosinophils and minimal mucus secretion in airways. Instead, the inflammatory responses seen in these mice had characteristics of Th1 effector cell recruitment, with higher numbers of neutrophils in BAL fluid than were found in WT controls. A shift toward Th1 activation was also reflected in the antibody isotype profile, with IL-4 -/-mice showing much lower OVA-specific IgG1 responses and higher IgG2a responses. These data are consistent with published results of many other researchers who have examined responses to protein antigens in IL-4 -/-mice, and reported either absent or markedly impaired Th2 responses (16, 19, 21, 46, 47) .
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The In contrast to the loss of Th2 activation in IL-4 -/-mice after inhalation priming, a much different outcome was observed when IL-4 -/-mice were initially exposed to OVA through the skin. Epicutaneously sensitized IL-4 -/-mice mounted Th2 responses of the same magnitude as those seen in WT mice after airway OVA challenge, with equivalent numbers of eosinophils present in BAL fluid, strong PAS-positive staining of airways indicating mucus hypersecretion, and production of high levels of IL-5 and IL-13 by lung inflammatory cells. Although others have reported IL-4-independent Th2 responses after infection of mice with various live pathogens (18, (24) (25) (26) (27) , to our knowledge this is the first demonstration of a completely IL-4-independent Th2 response to a protein antigen. Hogan et al. did report a small rise in BAL-fluid eosinophils after airway challenge of IL-4 -/-mice that had been previously sensitized intraperitoneally with OVA in alum, but these responses were markedly reduced in comparison to WT controls (23) . In contrast, our data show no deficit in Th2 induction after e.c. sensitization of IL-4 -/-mice, with airway inflammatory responses indistinguishable from those of WT mice.
In apparent contrast to our findings, Spergel et al.
recently reported impaired eosinophil recruitment into inflamed skin sites in IL-4 -/-mice using a model of e.c. protein sensitization similar to that described here (47) .
In their study, the local inflammatory response induced in skin after repeated e.c. exposures to soluble OVA was evaluated. Whereas WT mice had increased numbers of eosinophils at these sites, the inflammatory infiltrates in IL-4 -/-mice had significantly fewer eosinophils. In our study, however, we saw no deficit in recruitment of eosinophils into the airway after inhalation challenge of epicutaneously sensitized IL-4 -/-mice. This difference probably reflects distinct requirements for leukocyte emigration into tissue at these two sites of antigen challenge, i.e., the skin vs. the lung. Several factors contribute to leukocyte trafficking across microvascular endothelium, including various proinflammatory cytokines and specific interactions between adhesion molecules expressed by endothelial cells and their ligands on the surface of inflammatory cells. Thus, whereas cytokines secreted by IL-4 -/-Th2 effector cells, including IL-5 and IL-13, may be sufficient for initiation of an inflammatory response and recruitment of eosinophils into the lung, control of leukocyte migration into skin may be more specifically dependent on IL-4. With regard to eosinophils in
Figure 7
Cellular composition of BAL fluid after airway challenge of epicutaneously sensitized Stat6 -/-mice. C57BL/6 WT or Stat6 -/-mice were initially exposed to e.c. OVA (100 µg) on day 0, and then challenged with i.n. OVA (25 µg) on days 14, 15, 18, and 19. On day 21, mice were sacrificed, BAL was performed, and total cell yield and differential counts in cytospin preparations from individual mice were determined. Data were pooled from 2 experiments and are reported as mean ± SEM of both the total number of cells recovered by BAL and the number of each cell type. Statistical significance between WT (n = 9) and Stat6 -/-(n = 7) groups was determined by unpaired Student's t test.
Figure 8
Cellular composition of BAL fluid after airway challenge of epicutaneously sensitized IL-4 -/-mice depleted of IL-13 in vivo. IL-4 -/-mice were initially exposed epicutaneously to either OVA (100 µg) in PBS or PBS alone on day 0, and then challenged with i.n. OVA (25 µg) on days 14, 15, 18, and 19. OVA-exposed mice also received intraperitoneal injections of either an IL-13 antagonist (IL-13Rα-Fc) or the Fc control (ctrl-Fc) every other day, from day -1 to day 19. On day 21, mice were sacrificed, BAL was performed, and total cell yield and differential counts in cytospin preparations from individual mice were determined. Data are reported as mean ± SEM (3 mice per group) of both the total number of cells recovered by BAL and the number of each cell type. Statistical significance between groups was determined by unpaired Student's t test. *P < 0.05 for PBS-exposed vs. OVA-exposed groups; P = 0.009 for eosinophils IL-13Rα-Fc vs. ctrl-Fc-treated groups.
particular, interaction of the α4-integrin VLA-4 on the eosinophil surface with its ligand VCAM-1 on endothelial cells is very important in allowing egress of eosinophils into inflamed tissue (48) . Furthermore, IL-4 can upregulate VCAM-1 expression on endothelial cells (49) . Thus, a lack of IL-4 could result in decreased VCAM-1 and a subsequent defect in eosinophil migration. However, Spergel et al. reported no detectable difference in VCAM-1 staining of epicutaneously exposed skin sites between WT mice and IL-4 -/-mice (47). Still, the possibility remains that another IL-4-dependent adhesive interaction exists that is needed for eosinophils to migrate across cutaneous, but not pulmonary, microvasculature. The role of IL-4 in Th2 skewing is tightly linked to its ability to activate the STAT6 intracellular signaling pathway (36, 37) . Binding of IL-4 to the IL-4 receptor α chain (IL-4Rα) results in phosphorylation of STAT6; studies by several groups have established that the ability to generate Th2 responses is markedly hampered in Stat6 -/-mice (38, 50-52). Our finding of strikingly impaired Th2 activation after e.c. OVA exposure of Stat6 -/-mice is in agreement with these studies, and confirms that the Th2 responses in our system also work via the STAT6 signaling pathway. It follows that a factor other than IL-4 must be capable of inducing STAT6 activation in our system, because effective Th2 activation did occur after e.c. OVA exposure of IL-4 -/-mice. IL-13 was a likely candidate because it too can induce activation of STAT6 by binding to the highaffinity IL-13 receptor complex, one component of which is the IL-4Rα chain (39, 40, 53, 54) . Moreover, it has recently been found that IL-13 is the factor responsible for IL-4-independent Th2 generation in IL-4 -/-mice infected with Nippostrongylus (28, 29) . A major role for IL-13 in allergic airway inflammatory responses in mice has also been demonstrated (55, 56) . To confirm that IL-13 was the STAT6-inducing factor mediating IL-4-independent Th2 activation in our system after e.c. sensitization, we blocked IL-13 activity in vivo by administration of an IL-13 antagonist. As expected, depletion of IL-13 in epicutaneously sensitized IL-4 -/-mice resulted in a loss of Th2 activation, indicating that IL-13 could effectively stimulate generation of a Th2 response after e.c. protein exposure, even in the absence of IL-4. It should be noted that unlike human T cells, murine T cells have not been shown to respond to IL-13 (39) . Therefore, the exact mechanism by which IL-13 mediates Th2 activation in our system and in other models (27) (28) (29) remains unclear. It may be that expression of IL-13 receptors by murine T cells occurs only under specific conditions of T-cell activation in vivo that have yet to be duplicated ex vivo or in vitro. Alternatively, Th2 differentiation may occur as an indirect effect after IL-13-induced STAT6 activation of another cell population that responds to IL-13, such as macrophages or dendritic cells (38, 57, 58) .
In summary, this study describes an interesting dichotomy in the IL-4 dependence of Th2 responses generated by exposure of two different anatomic sites to soluble protein antigen. Whereas induction of Th2 inflammatory responses by primary exposure to i.n. antigen was significantly impaired in IL-4 -/-mice, Th2 responses equivalent to those in WT mice were still generated in IL-4 -/-mice after e.c. antigen exposure. The lack of Th2 activation in Stat6 -/-mice after e.c. sensitization indicated that a factor other than IL-4, probably IL-13, was capable of inducing STAT6 activation in epicutaneously sensitized IL-4 -/-mice. Indeed, in vivo depletion of IL-13 in epicutaneously sensitized IL-4 -/-mice did result in a loss of the Th2 response. This study provides particularly relevant information with regard to the immunoregulatory factors controlling Th2 activation at sites of natural allergen exposure, namely the skin and lung. In addition, the data point to the skin as a powerful site for Th2 activation, even in the absence of IL-4, and raise new questions about its relative contribution in early sensitization of atopic individuals.
